A large pooled analysis confirms longer non-steroidal anti-androgen (e.g. bicalutamide) use in conjunction with LHRH agonists (e.g. Lupron) beyond the initial 1–2 months was associated with more early ADT discontinuation and worse survival for men with prostate cancer, supporting limiting its use to short-term flare protection versus prolonged combined anti-androgen exposure. | Takayesu, Int J Radiat Oncol Biol Phys 2026
